Participated · Series B · Jul 2023

Laplace Interventional is a Minnesota-based medical device company developing a prosthetic transcatheter tricuspid valve delivered via a minimally invasive procedure to avoid open-heart surgery. The device is intended to improve quality of life for patients with tricuspid regurgitation. The company has completed an Early Feasibility Study (EFS) experience treating three patients (all discharged home within 1–2 days) and has enrolled 22 patients in the U.S. EFS and 25 patients globally. Laplace announced a $22M Series C financing to support completion of its U.S. and OUS feasibility studies and to work toward initiating a pivotal study. The company added Ned Scheetz of Aphelion Capital to its board as part of the financing announcement. The device remains in development and is not approved or cleared by the FDA or any other regulatory body. Laplace Interventional is a Minneapolis, MN–based medical device company developing a transcatheter prosthetic valve system to treat patients with tricuspid regurgitation. The device is designed to be delivered through patient vasculature, avoiding open‑heart surgery and aiming to increase life expectancy and improve quality of life for patients with TR. The technology is in an early stage of development and is not approved or cleared by the FDA or other regulatory bodies. The company intends to use the new capital to pursue first‑in‑human (FIH) and clinical feasibility evaluations of its valve system. Ramji Iyer is founder and CEO, and the company has recently added industry executives to its board, including Jenny Barba and Todd Mortier. Laplace Interventional is a Minnesota-based medical device company developing a transcatheter tricuspid valve technology. Its core product is a prosthetic valve designed for minimally invasive delivery that avoids open-heart surgery to treat tricuspid regurgitation. The company says the device aims to increase life expectancy and improve quality of life for patients with TR. Laplace recently closed a $7.9M Series A to fund progress toward preclinical milestones. Leadership added two directors to the board, including William Dai of ShangBay Capital, a participant in the round. The device remains in early-stage development and is not approved or cleared by the FDA or other regulatory bodies.